News stories about Benitec Biopharma Limited (NASDAQ:BNTC) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Benitec Biopharma Limited earned a news impact score of 0.15 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3010022997084 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
BNTC has been the topic of a number of analyst reports. ValuEngine raised shares of Benitec Biopharma Limited from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. Maxim Group reaffirmed a “hold” rating on shares of Benitec Biopharma Limited in a research note on Wednesday, August 30th.
Benitec Biopharma Limited (NASDAQ BNTC) traded down $0.06 during trading on Tuesday, hitting $2.70. 45,300 shares of the company were exchanged, compared to its average volume of 309,976. Benitec Biopharma Limited has a 52 week low of $1.30 and a 52 week high of $5.48.
About Benitec Biopharma Limited
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with MarketBeat.com's FREE daily email newsletter.